Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series

Fatobene, Giancarlo; Souza, Gabriela Rodriguez de; Rodrigues, Celso Arrais; Novis, Yana; Rocha, Vanderson

doi:10.1016/j.htct.2020.07.008

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the instability of the linker led to the release of the bound drug within 48 h, and approximately half of the antibodies were unconjugated, which resulted in a high risk of side effects (prolonged thrombocytopenia). The highly hydrophobic nature of calicheamicin, its lack of specificity and its tendency to be eliminated prompted the withdrawal of GO from the commercial market in 2010( 34 ). Subsequently, oncologists changed to a lower dose and schedule of GO and used it with the traditional chemotherapeutic agents daunorubicin and cytarabine (DA) in 2017( 35 ).…”

Section: First Generation Of Adcs: Gemtuzumab Ozogamicin (Go)mentioning

confidence: 99%

Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review)

Sun

Niu

et al. 2023

Mol Clin Oncol

View full text Add to dashboard Cite

Antibody-drug conjugates (ADCs) are anticancer drugs that combine cytotoxic small-molecule drugs (payloads) with monoclonal antibodies through a chemical linker and that transfer toxic payloads to tumor cells expressing target antigens. All ADCs are based on human IgG. In 2009, the Food and Drug Administration (FDA) approved gemtuzumab ozogamicin as the initial first-generation ADC. Since then, at least 100 ADC-related projects have been initiated, and 14 ADCs are currently being tested in clinical trials. The limited success of gemtuzumab ozogamicin has led to the development of optimization strategies for the next generation of drugs. Subsequently, experts have improved the first-generation ADCs and have developed second-generation ADCs such as ado-trastuzumab emtansine. Second-generation ADCs have higher specific antigen levels, more stable linkers and longer half-lives and show great potential to transform cancer treatment models. Since the first two generations of ADCs have served as a good foundation, the development of ADCs is accelerating, and third-generation ADCs, represented by trastuzumab deruxtecan, are ready for wide application. Third-generation ADCs are characterized by strong pharmacokinetics and high pharmaceutical activity, and their drug-to-antibody ratio mainly ranges from 2 to 4. In the past decade, the research prospects of ADCs have broadened, and an increasing number of specific antigen targets and mechanisms of cytotoxic drug release have been discovered and studied. To date, seven ADCs have been approved by the FDA for lymphoma, and three have been approved to treat breast cancer. The present review explores the function and development of ADCs and their clinical use in cancer treatment.

show abstract

Section: First Generation Of Adcs: Gemtuzumab Ozogamicin (Go)mentioning

confidence: 99%